Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Earnings for Tempest Therapeutics, Inc. (TPST)
Earnings in 2023 (TTM): $-29,491,000
According to Tempest Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-29,491,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Tempest Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-29,491,000 | $-29,491,000 |
| 2022 | $-35,709,000 | $-36,778,000 |
| 2021 | $-28,302,000 | $-29,550,000 |
| 2020 | $-19,208,000 | $-19,118,000 |
| 2019 | $-44,568,000 | $-44,568,000 |
| 2018 | $-27,177,000 | $-27,192,000 |
| 2017 | $-84,586,000 | $-84,578,000 |
| 2016 | $-82,059,000 | $-82,260,000 |
| 2015 | $-73,144,000 | $-73,219,000 |
| 2014 | $-49,520,000 | $-49,520,000 |
| 2013 | $-29,044,000 | $-29,044,000 |
| 2012 | $-13,510,000 | $-13,510,000 |